1887

Abstract

Millions of antibiotic prescriptions are written annually in the USA.

Probiotics reduce antibiotic-induced gastrointestinal side effects; however, the effect of probiotics on preserving gut microbial composition in response to antibiotics is not well understood.

To evaluate whether the addition of probiotics is capable of reverting the changes in alpha diversity and gut microbial composition commonly observed in adult participants receiving antibiotics.

A search was conducted by two researchers following the PRISMA guidelines using PubMed, Science Direct, Cochrane and Embase from January to December 2021 with the following inclusion criteria: (i) randomized clinical trials assessing the effect of antibiotics, probiotics or antibiotics+probiotics; (ii) 16S rRNA; (iii) adult participants; and (iv) in English. Once data was extracted in tables, a third researcher compared, evaluated and merged the collected data. The National Institutes of Health (NIH) rating system was utilized to analyse risk of bias.

A total of 29 articles (=11 antibiotics, =11 probiotics and =7 antibiotics+probiotics) met the inclusion criteria. The lack of standardization of protocols to analyse the gut microbial composition and the wide range of selected antibiotics/probiotics complicated data interpretation; however, despite these discrepancies, probiotic co-administration with antibiotics seemed to prevent some, but not all, of the gut microbial diversity and composition changes induced by antibiotics, including restoration of health-related bacteria such as .

Addition of probiotics to antibiotic interventions seems to preserve alpha diversity and ameliorate the changes to gut microbial composition caused by antibiotic interventions.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001625
2022-11-16
2024-02-27
Loading full text...

Full text loading...

References

  1. CDC Antibiotic Use in the United States 2018 Update: Progress and Opportunities Washington, DC, Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2018
    [Google Scholar]
  2. Institute of Medicine Forum on Microbial Threats Washington, DC: National Academies of Sciences, Engineering and Medicine; 2010
    [Google Scholar]
  3. Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev 2012; 70 (Suppl. 1):S38–S44 [View Article]
    [Google Scholar]
  4. Abeles SR, Jones MB, Santiago-Rodriguez TM, Ly M, Klitgord N et al. Microbial diversity in individuals and their household contacts following typical antibiotic courses. Microbiome 2016; 4:39 [View Article]
    [Google Scholar]
  5. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011; 108 (Suppl. 1):4554–4561 [View Article]
    [Google Scholar]
  6. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016; 14:e1002533 [View Article]
    [Google Scholar]
  7. Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota – a systematic review. J Infect 2019; 79:471–489 [View Article]
    [Google Scholar]
  8. Wang Z-J, Chen X-F, Zhang Z-X, Li Y-C, Deng J et al. Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microb Pathog 2017; 109:156–161 [View Article]
    [Google Scholar]
  9. Forssten S, Evans M, Wilson D, Ouwehand AC. Influence of a probiotic mixture on antibiotic induced microbiota disturbances. World J Gastroenterol 2014; 20:11878–11885 [View Article]
    [Google Scholar]
  10. Oh B, Kim JW, Kim BS. Changes in the functional potential of the gut microbiome following probiotic supplementation during Helicobacter pylori treatment. Helicobacter 2016; 21:493–503 [View Article]
    [Google Scholar]
  11. Li T, Teng D, Mao R, Hao Y, Wang X et al. A critical review of antibiotic resistance in probiotic bacteria. Food Res Int 2020; 136:109571 [View Article] [PubMed]
    [Google Scholar]
  12. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 2013; 7:e56–e67
    [Google Scholar]
  13. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JNV et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307:1959–1969 [View Article] [PubMed]
    [Google Scholar]
  14. Blaabjerg S, Artzi DM, Aabenhus R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – a systematic review and meta-analysis. Antibiotics 2017; 6:E21 [View Article]
    [Google Scholar]
  15. Ling Z, Liu X, Cheng Y, Luo Y, Yuan L et al. Clostridium butyricum combined with Bifidobacterium infantis probiotic mixture restores fecal microbiota and attenuates systemic inflammation in mice with antibiotic-associated diarrhea. Biomed Res Int 2015; 2015:582048 [View Article]
    [Google Scholar]
  16. Korpela K, Salonen A, Vepsäläinen O, Suomalainen M, Kolmeder C et al. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. Microbiome 2018; 6:182 [View Article]
    [Google Scholar]
  17. Haak BW, Lankelma JM, Hugenholtz F, Belzer C, de Vos WM et al. Long-term impact of oral vancomycin, ciprofloxacin and metronidazole on the gut microbiota in healthy humans. J Antimicrob Chemother 2019; 74:782–786 [View Article] [PubMed]
    [Google Scholar]
  18. Lankelma JM, Cranendonk DR, Belzer C, de Vos AF, de Vos WM et al. Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study. Gut 2017; 66:1623–1630 [View Article] [PubMed]
    [Google Scholar]
  19. Burdet C, Grall N, Linard M, Bridier-Nahmias A, Benhayoun M et al. Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens. Antimicrob Agents Chemother 2019; 63:e02244-18 [View Article]
    [Google Scholar]
  20. Heinsen F-A, Knecht H, Neulinger SC, Schmitz RA, Knecht C et al. Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin. Gut Microbes 2015; 6:243–254 [View Article] [PubMed]
    [Google Scholar]
  21. Reijnders D, Goossens GH, Hermes GDA, Neis E, van der Beek CM et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab 2016; 24:63–74 [View Article]
    [Google Scholar]
  22. Burdet C, Nguyen TT, Duval X, Ferreira S, Andremont A et al. Impact of antibiotic gut exposure on the temporal changes in microbiome diversity. Antimicrob Agents Chemother 2019; 63:e00820-19 [View Article]
    [Google Scholar]
  23. Haak BW, Argelaguet R, Kinsella CM, Kullberg RFJ, Lankelma JM et al. Integrative transkingdom analysis of the gut microbiome in antibiotic perturbation and critical illness. mSystems 2021; 6:e01148-20 [View Article]
    [Google Scholar]
  24. Horii T, Suzuki S, Takano C, Shibuya H, Ichijima R et al. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol 2021; 36:3314–3321 [View Article]
    [Google Scholar]
  25. Fodor AA, Pimentel M, Chey WD, Lembo A, Golden PL et al. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes 2019; 10:22–33 [View Article] [PubMed]
    [Google Scholar]
  26. Siu J, Mackenzie BW, Klingler L, Biswas K, Wang Y et al. Sinonasal and gastrointestinal bacterial composition and abundance are stable after 1 week of once-daily oral antibiotic treatment for chronic rhinosinusitis. Int Forum Allergy Rhinol 2021; 11:1355–1366 [View Article] [PubMed]
    [Google Scholar]
  27. Kaku N, Matsumoto N, Sasaki D, Tsuda K, Kosai K et al. Effect of probiotics on gut microbiome in patients with administration of surgical antibiotic prophylaxis: a randomized controlled study. J Infect Chemother 2020; 26:795–801 [View Article]
    [Google Scholar]
  28. De Wolfe TJ, Eggers S, Barker AK, Kates AE, Dill-McFarland KA et al. Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection. PLoS One 2018; 13:e0204253 [View Article]
    [Google Scholar]
  29. Bloemendaal M, Szopinska-Tokov J, Belzer C, Boverhoff D, Papalini S et al. Probiotics-induced changes in gut microbial composition and its effects on cognitive performance after stress: exploratory analyses. Transl Psychiatry 2021; 11:300 [View Article]
    [Google Scholar]
  30. Botelho PB, Ferreira MVR, Araújo A de M, Mendes MM, Nakano EY. Effect of multispecies probiotic on gut microbiota composition in individuals with intestinal constipation: a double-blind, placebo-controlled randomized trial. Nutrition 2020; 78:110890 [View Article]
    [Google Scholar]
  31. Liu S, Liu H, Chen L, Liang S-S, Shi K et al. Effect of probiotics on the intestinal microbiota of hemodialysis patients: a randomized trial. Eur J Nutr 2020; 59:3755–3766 [View Article] [PubMed]
    [Google Scholar]
  32. Gomes AC, Hoffmann C, Mota JF. Gut microbiota is associated with adiposity markers and probiotics may impact specific genera. Eur J Nutr 2020; 59:1751–1762 [View Article] [PubMed]
    [Google Scholar]
  33. Harata G, Kumar H, He F, Miyazawa K, Yoda K et al. Probiotics modulate gut microbiota and health status in Japanese cedar pollinosis patients during the pollen season. Eur J Nutr 2017; 56:2245–2253 [View Article] [PubMed]
    [Google Scholar]
  34. Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun 2018; 70:48–60 [View Article]
    [Google Scholar]
  35. Kim CS, Cha L, Sim M, Jung S, Chun WY et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci 2021; 76:32–40 [View Article]
    [Google Scholar]
  36. Halkjær SI, de Knegt VE, Lo B, Nilas L, Cortes D et al. Multistrain probiotic increases the gut microbiota diversity in obese pregnant women: results from a randomized, double-blind placebo-controlled study. Curr Dev Nutr 2020; 4:zaa095 [View Article]
    [Google Scholar]
  37. Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: a pilot randomized clinical trial. United European Gastroenterol J 2018; 6:604–613 [View Article]
    [Google Scholar]
  38. Hibberd AA, Yde CC, Ziegler ML, Honoré AH, Saarinen MT et al. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. Benef Microbes 2019; 10:121–135 [View Article] [PubMed]
    [Google Scholar]
  39. Rahayu ES, Mariyatun M, Putri Manurung NE, Hasan PN, Therdtatha P et al. Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults. World J Gastroenterol 2021; 27:107–128 [View Article] [PubMed]
    [Google Scholar]
  40. MacPherson CW, Mathieu O, Tremblay J, Champagne J, Nantel A et al. Gut bacterial microbiota and its resistome rapidly recover to basal state levels after short-term amoxicillin-clavulanic acid treatment in healthy adults. Sci Rep 2018; 8:11192 [View Article]
    [Google Scholar]
  41. Oh B, Kim BS, Kim JW, Kim JS, Koh SJ et al. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: randomized controlled trial. Helicobacter 2016; 21:165–174 [View Article]
    [Google Scholar]
  42. Chen L, Xu W, Lee A, He J, Huang B et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine 2018; 35:87–96 [View Article]
    [Google Scholar]
  43. Kabbani TA, Pallav K, Dowd SE, Villafuerte-Galvez J, Vanga RR et al. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes 2017; 8:17–32 [View Article]
    [Google Scholar]
  44. Cárdenas PA, Garcés D, Prado-Vivar B, Flores N, Fornasini M et al. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur J Clin Microbiol Infect Dis 2020; 39:1365–1372 [View Article]
    [Google Scholar]
  45. Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44:117–164 [View Article] [PubMed]
    [Google Scholar]
  46. Akhavan BJ, Khanna NR, Vijhani P. Amoxicillin [updated 27 August 2020] ( https://www.ncbi.nlm.nih.gov/books/NBK482250/) Treasure Island, FL: StatPearls; 2020
    [Google Scholar]
  47. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 1997; 54:679–708 [View Article]
    [Google Scholar]
  48. Nord CE. Microbiological properties of tinidazole: spectrum, activity and ecological considerations. J Antimicrob Chemother 1982; 10 (Suppl. A):35–42 [View Article]
    [Google Scholar]
  49. Bui T, Preuss CV. Cephalosporins [updated 17 February 2021] ( https://www.ncbi.nlm.nih.gov/books/NBK551517/) Treasure Island, FL: StatPearls; 2021
    [Google Scholar]
  50. Chamberlain RE. Chemotherapeutic properties of prominent nitrofurans. J Antimicrob Chemother 1976; 2:325–336 [View Article]
    [Google Scholar]
  51. Antonoplis A, Zang X, Wegner T, Wender PA, Cegelski L. Vancomycin-arginine conjugate inhibits growth of carbapenem-resistant E. coli and targets cell-wall synthesis. ACS Chem Biol 2019; 14:2065–2070 [View Article]
    [Google Scholar]
  52. Kim H, Kim T, Kang J, Kim Y, Kim H. Is Lactobacillus gram-positive? A case study of Lactobacillus iners. Microorganisms 2020; 8:969 [View Article]
    [Google Scholar]
  53. Butta H, Sardana R, Vaishya R, Singh KN, Mendiratta L. Bifidobacterium. an emerging clinically significant metronidazole-resistant anaerobe of mixed pyogenic infections. Cureus 2017; 9:e1134 [View Article]
    [Google Scholar]
  54. Naito Y, Uchiyama K, Takagi T. A next-generation beneficial microbe: Akkermansia muciniphila. J Clin Biochem Nutr 2018; 63:33–35 [View Article]
    [Google Scholar]
  55. Zou Y, Lin X, Xue W, Tuo L, Chen MS et al. Characterization and description of Faecalibacterium butyricigenerans sp. nov. and F. longum sp. nov., isolated from human faeces. Sci Rep 2021; 11:11340 [View Article]
    [Google Scholar]
  56. Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M et al. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 2012; 3:121–134 [View Article] [PubMed]
    [Google Scholar]
  57. Mandell L, Moran AP, Cocchiarella A, Houghton J, Taylor N et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 2004; 72:6446–6454 [View Article] [PubMed]
    [Google Scholar]
  58. Lim JY, Yoon J, Hovde CJ. A brief overview of Escherichia coli O157:H7 and its plasmid O157. J Microbiol Biotechnol 2010; 20:5–14 [PubMed]
    [Google Scholar]
  59. Blatchford P, Stoklosinski H, Eady S, Wallace A, Butts C et al. Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: a randomised controlled human trial. J Nutr Sci 2017; 6:e52 [View Article]
    [Google Scholar]
  60. Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 2013; 16:255–261 [View Article] [PubMed]
    [Google Scholar]
  61. Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J 2017; 11:841–852 [View Article] [PubMed]
    [Google Scholar]
  62. Chen S, Jiang P-P, Yu D, Liao G-C, Wu S-L et al. Effects of probiotic supplementation on serum trimethylamine-N-oxide level and gut microbiota composition in young males: a double-blinded randomized controlled trial. Eur J Nutr 2021; 60:747–758 [View Article] [PubMed]
    [Google Scholar]
  63. De Filippis F, Pasolli E, Ercolini D. Newly explored Faecalibacterium diversity is connected to age, lifestyle, geography, and disease. Curr Biol 2020; 30:4932–4943 [View Article]
    [Google Scholar]
  64. Moosavi SM, Akhavan Sepahi A, Mousavi SF, Vaziri F, Siadat SD. The effect of Faecalibacterium prausnitzii and its extracellular vesicles on the permeability of intestinal epithelial cells and expression of PPARs and ANGPTL4 in the Caco-2 cell culture model. J Diabetes Metab Disord 2020; 19:1061–1069 [View Article] [PubMed]
    [Google Scholar]
  65. Geerlings SY, Kostopoulos I, de Vos WM, Belzer C. Akkermansia muciniphila in the human gastrointestinal tract: when, where, and how?. Microorganisms 2018; 6:75 [View Article]
    [Google Scholar]
  66. Claesson MJ, van Sinderen D, O’Toole PW. The genus Lactobacillus – a genomic basis for understanding its diversity. FEMS Microbiol Lett 2007; 269:22–28 [View Article]
    [Google Scholar]
  67. Qin P, Zou Y, Dai Y, Luo G, Zhang X et al. Characterization a novel butyric acid-producing bacterium Collinsella aerofaciens subsp. Shenzhenensis subsp. nov. Microorganisms 2019; 7:78 [View Article]
    [Google Scholar]
  68. Hirayama M, Nishiwaki H, Hamaguchi T, Ito M, Ueyama J et al. Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate. PLoS One 2021; 16:e0260451 [View Article]
    [Google Scholar]
  69. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007; 20:593–621 [View Article] [PubMed]
    [Google Scholar]
  70. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014; 15:382–392 [View Article] [PubMed]
    [Google Scholar]
  71. Stephen-Victor E, Crestani E, Chatila TA. Dietary and microbial determinants in food allergy. Immunity 2020; 53:277–289 [View Article]
    [Google Scholar]
  72. Kang E, Crouse A, Chevallier L, Pontier SM, Alzahrani A et al. Enterobacteria and host resistance to infection. Mamm Genome 2018; 29:558–576 [View Article] [PubMed]
    [Google Scholar]
  73. Louie TJ, Cannon K, Byrne B, Emery J, Ward L et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 (Suppl. 2):S132–S142 [View Article]
    [Google Scholar]
  74. Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65:749–756 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001625
Loading
/content/journal/jmm/10.1099/jmm.0.001625
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error